Huons Presents Preclinical Results for Fibrostenotic Crohn's Disease Treatment
Inhibition of ECM cross-linking and intestinal fibrosis
"Developing it as a first-in-class drug"
Huons said on October 20 that it had presented poster findings from preclinical studies of HUC1A-626, a selective TG2 inhibitor, at UEG Week 2026, the annual scientific meeting of United European Gastroenterology, held in Barcelona, Spain, from October 17 to 20 (local time).
HUC1A-626 is a compound Huons is developing to treat fibrostenotic Crohn's disease (FSCD). Biologics used to treat FSCD are effective at controlling inflammation, but have limitations in suppressing or reversing fibrotic lesions that have already developed.
Huons researchers present a poster on preclinical study findings for HUC1A-626, a candidate treatment for fibrostenotic Crohn's disease, at UEG Week 2026, the annual scientific meeting of the United European Gastroenterology, held in Barcelona, Spain, on the 18th (local time). Huons
View original imageTG2 is an enzyme that abnormally cross-links extracellular matrix (ECM) proteins and prevents accumulated matrix from breaking down, acting like an adhesive that hardens tissue. Huons researchers identified HUC1A-626, an oral TG2 inhibitor designed to act locally in the intestines, and evaluated its antifibrotic effects from multiple angles in cell and animal models.
HUC1A-626 showed high inhibitory potency and selectivity against TG2. In experiments using human colon-derived fibroblasts, researchers confirmed antifibrotic effects across multiple pathways through TG2 inhibition. In animal models, fibrotic lesions and insoluble collagen levels decreased, and antifibrotic effects were observed in both histological and quantitative analyses.
Based on these findings, Huons plans to present a new treatment strategy that differentiates the drug from existing treatments and targets the underlying cause of the disease.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Park Kyung-mi, Huons' Executive Vice President and Head of Research and Development, said, "We will develop it as a first-in-class innovative drug that breaks the cycle of fibrosis that continues even after inflammation subsides, offering a fundamental solution to patients with fibrostenotic Crohn's disease."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.